ArticleAntimicrobial resistance and infection control2018
Molecular characterization of extended spectrum β -lactamases enterobacteriaceae causing lower urinary tract infection among pediatric population.
Article in Antimicrobial resistance and infection control, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in sub-Saharan Africa: a systematic review and meta-analysis from a One Health perspective.BMC infectious diseases · 2025Pooled it
- A systematic review and meta-analysis on the prevalence of extended-spectrum beta-Lactamase-ProducingAfrican health sciences · 2024Pooled it
- Rodent-Related Zoonotic Pathogens at the Human-Animal-Environment Interface in Qatar: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021Pooled it
- Antibiotic resistance profiles and co-occurrence of ESBL and AmpC β-lactamase genes in ESBL-producing Gram-negative bacteria of clinical origin.BMC microbiology · 2026Article
- Extended Spectrum Beta-Lactamase Production and Multidrug-Resistant Enterobacterales Among Patients With Symptoms of Urinary Tract Infection in Addis Ababa, Ethiopia.BioMed research international · 2026Article
- Molecular Characterization and Antibiotic Resistance of Broad-SpectrumInternational journal of microbiology · 2026Article
- Extended spectrum beta-lactamase producing Escherichia coli encoding aminoglycoside and fluoroquinolone resistant genes in urinary tract infection patients in a tertiary hospital in Nigeria.BMC infectious diseases · 2025Article
- A Snapshot of Antimicrobial Resistance in Semi-Wild Oryx: Baseline Data from Qatar.Antibiotics (Basel, Switzerland) · 2025Article
- Article
- Urinary Tract Infections among Febrile Infants in Qatar: Extended-Spectrum-Beta-Lactamase (ESBL)-Producing Versus Non-ESBL Organisms.Antibiotics (Basel, Switzerland) · 2024Article
- Article
- Application of Antimicrobial Peptides as Diagnostic Biosensors.Analytical chemistry · 2024Article
- Detection of extended-spectrum β-lactamase-producingVeterinary world · 2023Review
- Rodent-borne zoonoses in Qatar: A possible One-Health framework for the intervention of future epidemic.One health (Amsterdam, Netherlands) · 2023Review
- Article
- Urinary tract infections in children from the Gulf Cooperation Council countries: a literature review (2011-2022).Frontiers in pediatrics · 2023Review
- A multicentre study to determine thePeerJ · 2023Article
- Prevalence and genetic characterization of clinically relevant extended-spectrum β-lactamase-producingFrontiers in antibiotics · 2023Review
- Clonal groups of extended-spectrum β-lactamase and biofilm producing uropathogenicPathogens and global health · 2022Article
- Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates.BMC microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The β-lactam antibiotics have traditionally been the main treatment of Enterobacteriaceae infections, nonetheless, the emergence of species producing β- Lactamases has rendered this class of antibiotics largely ineffective. There are no published data on etiology of urinary tract infections (UTI) and antimicrobial resistance profile of uropathogens among children in Qatar. The aim of this study is to determine the phenotypic and genotypic profiles of antimicrobial resistant Enterobacteriaceae among children with UTI in Qatar. Methods: Bacteria were isolated from 727 urine positive cultures, collected from children with UTI between February and June 2017 at the Pediatric Emergency Center, Doha, Qatar. Isolated bacteria were tested for antibiotic susceptibility against sixteen clinically relevant antibiotics using phoenix and Double Disc Synergy Test (DDST) for confirmation of extended-spectrum beta-lactamase (ESBL) production. Existence of genes encoding ESBL production were identified using polymerase chain reaction (PCR). Statistical analysis was done using non-parametric Kappa statistics, Pearson chi-square test and Jacquard's coefficient. Results: 201 (31.7%) of samples were confirmed as Extended Spectrum β -Lactamases (ESBL) Producing Enterobacteriaceae. The most dominant pathogen was Conclusions: Our data indicates an escalated problem of ESBL in pediatrics with UTI, which mandates implementation of regulatory programs to reduce the spread of ESBL producing Enterobacteriaceae in the community. The use of cephalosporins, aminoglycosides (gentamicin) and trimethoprim/sulfamethoxazole is compromised in Qatar among pediatric population with UTI, leaving carbapenems and amikacin as the therapeutic option for severe infections caused by ESBL producers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.